Our research found that Bread Financial’s 2-year CD is one of the best 2-year CDs currently available, earning a 4.4-star rating from our research team. The account earns a solid APY, compounds ...

Mylan’s long-awaited rival for Teva’s blockbuster multiple sclerosis drug Copaxone has been approved in the US, putting a large chunk of the Israeli firm’s revenues at risk. The timing could not have ...

18 months after it opened an investigation into Teva to see if it illegally blocked generic versions of its big-selling multiple sclerosis drug Copaxone, the European Commission has said it thinks the ...

There is no recent news for this security. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your ...